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Abstract
Objective: The aim of the study was to compare the incidence of post-operative complications between
those patients that received TachoSil® to the transection surface of the liver vs. those that received
Surgicel®.
Methods: Retrospective study of a prospective database in a tertiary hospital. Primary endpoints were
overall complications. Secondary endpoints were liver surgery-specific composite endpoint, major com-
plications and hospital stay. Uni- and multivariate analysis of predictive factors for complications
and subgroup analysis were performed.
Results: One hundred thirty-three liver resections were performed between 9 November 2007 and 2
November 2011: 64 with TachoSil® and 69 with Surgicel® application. Both groups were equivalent
concerning demographic, clinical and major intra-operative data. No significant differences were
observed in overall complication rate (62.5% vs. 62.3%), liver surgery-specific composite endpoint
(12.5% vs. 18.8%), major complication rate (18.7% vs. 24.6%) and median hospital stay (13 vs. 10 days)
for TachoSil® and Surgicel® application, respectively. Predictive factors for complications in multivariate
analysis were: American Society of Anesthesiology Score3 and duration of surgery >240 min. Subgroup
analysis found a reduced complication rate with TachoSil® for major hepatectomy.
Conclusion: The results of the present study suggest that the routine use of TachoSil® after a liver
resection does not reduce the overall complication rate compared with Surgicel® application. However,
TachoSil® may be beneficial in a major hepatectomy.
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Introduction
Liver resection is still an intervention with considerable morbi-
dity in spite of intensive study.1,2 Liver-specific complications are
observed in 10% to 20% of patients after a liver resection in
high-volume centres.3 Resection surface-related complications
such as a biliary fistula appear with a frequency of 4% to 12%4–6
and are associated with an increased rate of sepsis, liver failure,
mortality and longer hospital stay.5 Peri-operative bleeding may
require a transfusion and re-operation, increased mortality and
prolonged hospital stay.7 Predictive factors for peri-operative
complications after liver resection have been reported by several
authors and include a high ASA (American Society of Anesthe-
siologists) score, low serum albumin, major liver resection,
peri-operative transfusion, prolonged operative time, smoking,
jaundice, major biliary procedures, extrahepatic procedures and
prolonged ischaemic time.1,2,4–9
Topical haemostatic agents are widely used in liver surgery. A
Dutch Survey showed that 49% of liver surgeons routinely used
and 37% occasionally used topical haemostatic agents in liver
resection. It is believed that topical haemostatic agents may reduce
resection surface-related complications.10
Several techniques were studied for treating the liver resection
surface. Fibrin glue sealant was studied by Figueras et al. in a large
randomized trial and showed no efficacy for reducing overall-
and liver-specific complications.11 Frilling et al. studied a carrier-
bound fibrin sealant (TachoSil®) in a randomized trial and a
shorter time to haemostasis was reported vs. argon beamer.
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However, the bile leakage and complication rate were not different
between both groups.12 A prospective study by Briceno et al. found
an advantage for carrier-bound fibrin sealants for reducing drain
output, post-operative transfusion requirements and moderate-
to-severe post-operative complications in major liver resections.13
Several authors suggested that fibrin sealants may reduce biliary
fistulae.4,14–16 However, the available data about fibrin sealant
use in liver resection are heterogenous and there is still a lack of
evidence supporting its routine use.10,17
Two types of topical haemostatic agents are used in the authors’
institution: TachoSil® (Nycomed Pharma) is a ready-to use fixed
combination of a collagen sponge coated with a fibrinogen and
thrombin layer and Surgicel®-Original (Ethicon) is an oxidized
cellulose fleece providing a matrix for coagulation. The aim of
the study was to compare the incidence of post-operative com-
plications between those patients that received TachoSil® to the
transection surface of the liver vs. those that received Surgicel®.
A novelty of the present study was the analysis of the recently
proposed liver surgery-specific composite endpoint3 and the
comparison of two topical haemostatic agents.
Patients and methods
The study was performed in a single institution and included all
patients who underwent a liver resection between 9 November
2007 and 2 November 2011. The data were retrieved from a pro-
spective liver resection database and retrospectively analysed.
Patients who required extrahepatic procedures such as a simulta-
neous colorectal resection or others were included in the study,
as well as emergency interventions. All patients gave informed
written consent for surgery and data collection. Ethics approvals
were not required because of the retrospective monocentric
study design and local data analysis without data transmission.18
Patients were followed-up for at least 3 months.
Surgical technique and peri-operative management
Briefly, a bilateral subcostal incision with an upper midline exten-
sion was used. Ultrasonography was performed routinely. Lymph
node sampling or dissection was performed if indicated. A liver
parenchyma transection was performed under intermittent portal
triad clamping. A parenchyma transection was performed by
the clamp crushing technique.19 Haemostasis and biliostasis was
achieved by metallic clips, irrigated bipolar coagulation or liga-
tures. In a right or left hepatectomy, the corresponding pedicle was
transected after clamping with a vascular clamp and a running
suture with a non-absorbable monofilament was performed.
During a right hepatectomy, the right hepatic vein was transected
using a vascular stapler. A bile leakage test was routinely per-
formed.Methylene-blue dyed saline solution was injected through
the cystic duct and sites of bile leakage were repaired by fine
sutures. Haemostasis was completed with bipolar coagulation.
Finally, TachoSil® (Fig. 1) or Surgicel® (Fig. 2) was applied on the
resection surface. In the first 2 years of the study, TachoSil® was
quasi systematically (> 80%) used. Surgicel® was only occasionally
used in minor liver resections. Since December 2009, the authors
have changed their practice and Surgicel® was increasingly used
for all liver resections and became the standard topical haemo-
static agent in 2011. A multitubular silicon drain (Coloplast) was
placed routinely in the resected space. In the cirrhotic liver drain-
age was not performed as it has been shown to increase post-
operative morbidity.20 Blood loss was estimated by calculating the
Figure 1 The liver resection surface after a left hepatectomy
and lymph node dissection for intrahepatic cholangiocarcinoma
sealed with two TachoSil® sponges (9.5 ¥ 4.8 and 4.8 ¥ 4.8 cm). The
smaller sponge was divided in two. Cholangiography catheter was
still in place. Post-operative hospital stay was 9 days and uneventful
Figure 2 The liver resection surface after a right hepatectomy for
intrahepatic cholangiocarcinoma with Surgicel® application (10 ¥
20 cm). The liver presented major steatosis. Cholangiography cath-
eter was still in place. Post-operative hospital stay was 10 days and
uneventful
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aspiration volume. A red blood cell transfusion was given when
the haemoglobin level dropped below 8 g/dl and according to
haemodynamic tolerance, pathology, age and co-morbidity.
Post-operatively patients were monitored in the intensive care
unit for at least 24 h. Measurements of serum alanine amino-
transferase, aspartate aminotransferase, bilirubin, albumin, pro-
thrombin time, haemoglobin, creatinine and urea were recorded
daily for at least 5 days. An abdominal computer tomography scan
or ultrasound was performed routinely before hospital discharge
for detection of complications and to provide a reference imaging
for oncological follow-up. Abdominal drains were removed when
the liquid was clear and the volume less than 50 ml/day. The
bilirubin level was measured in the drainage liquid and compared
with the serum level if bile leakage was suspected. Culture of the
drainage liquid was performed if an infection was suspected.
Outcome measures
The primary endpoint was the overall complication rate. Second-
ary endpoints were a liver surgery-specific composite endpoint,3
major complications, bile leakage, 30- and 90-day mortality and
hospital stay. Outcome data were prospectively recorded in the
liver resection database.
Definitions
Overall complications were defined as any deviation from an
uneventful post-operative course within 90 days after surgery
and included: infectious complications (surgical site, pulmonary,
venous catheter, urinary tract, cholangitis and sepsis), liver-
specific complications and other complications (gastrointestinal,
cardiopulmonary, thrombosis, confusion, etc). The severity of
complications were defined according to the Clavien-Dindo
classification.21
The liver-specific complications were defined according to the
liver surgery-specific composite endpoint described by van den
Broek et al.3 and included: ascites, liver failure, bile leakage, intra-
abdominal hemorrhage, intra-abdominal abscess and mortality,
all within 90 days after initial surgery and with a Clavien-Dindo
grade  3.
A major hepatectomy was defined as the resection of 3 or more
liver segments. The Brisbane terminology was used for classifica-
tion of the type of liver resection.22 Bile leakage and hepatic insuf-
ficiency were defined according to the International Study Group
of Liver Surgery (ISGLS).23,24 A repeat hepatectomy was defined as
any liver resection performed in a patient who had previously
undergone a partial hepatectomy. Extrahepatic procedures were
defined as partial or total resection of other organs (colon,
rectum, small intestine, stomach, pancreas, diaphragm and
adrenal gland) and bilio-enteric anastomosis. A cholecystectomy,
liver biopsy and lymph node sampling or dissection were not
considered as extrahepatic procedures. Mortality was defined as
death within 30 and 90 days after surgery. Hospital stay was
defined as post-operative hospital stay.
Statistical analysis
Continuous variables were reported as median with range and
compared with a non-parametric Mann–Whitney test. Categori-
cal variables were compared with the c2 or Fisher’s exact test, as
appropriate. All statistical tests were two-sided, and P < 0.050 was
considered significant. To assess whether other parameters, apart
from the main variable of the study (TachoSil® or Surgicel® appli-
cation) may have influenced the development of complications, a
uni- and multivariate analysis was performed. Subgroup analysis
was performed to identify a group of patients who may benefit
from fibrin sealant use. A power analysis was not performed
owing to the retrospective study design.25
Results
One hundred thirty-three liver resections were performed in
108 patients between 9 November 2007 and 2 November 2011.
Twenty-five (18.8%) repeat liver resections were performed: 24 for
colorectal liver metastases and one for a recurrent hepatocellular
carcinoma. No patient was excluded. Patients’ characteristics are
shown in Table 1. Surgical procedures are shown in Table 2. Intra-
operative data are shown in Table 3. The median (range) number
of TachoSil® sponges used per patient in the TachoSil® group was
1 (1–4) with a 102 patches in total used; however, for a large
resection surface at least two patches (9.5 ¥ 4.8 cm) were needed
to cover the resection surface (Fig. 1). The median duration of
surgery was 265 min in the first 66 patients and 240 min in the
next 67 patients (P = 0.023). The median duration of all 133 liver
resections was 240 min and was used for the quantalization of
duration data.
Complications
Fifty patients (37.6%) had an uneventful post-operative course.
Eighty-three patients (62.4%) had complications. Sixty patients
(45.1%) had an infectious complication. Twenty-one patients
(15.8%) had a liver-specific complication of at least grade 3
according to the Clavien-Dindo classification. Sixteen patients
(12.0%) had other complications (no infection and no liver spe-
cific). Some patients had more than one complication. Twenty-
nine patients (21.8%) had a major complication (Clavien-Dindo
3). Data are shown in Table 4.
Bile leakage
Twelve patients (9.0%) had a bile leakage. One patient 0.7%) was
re-operated as bile was leaking from the right subcostal incision:
a multitubular silicon drain was placed for drainage and the
laparotomy wound was closed. Three patients (2.2%) had percu-
taneous ultrasonography guided drainage and in 8 patients
(6.0%) the intra-operatively placed drainage was left in place
(duration of drainage 10–45 days) until the fistula subsided
spontaneously. No patient with a bile leakage died.
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Percutaneous radiological drainage
Nine patients (6.8%) had a percutaneous radiological drainage:
biliary fistula (3 patients; 2.2%), infected pleural collections
(2 patients; 1.5%) and infected intra-abdominal collections
(4 patients; 3.0%).
Re-operation
Four patients (3.0%) were re-operated because of the following: 1
bile leakage in the TachoSil® group and 2 haemoperitoneum and 1
septicaemia in the Surgicel® group. The causes of haemoperito-
neum were bleeding of the left hepatic artery, and bleeding of a
small vein of the hepatic pedicle after lymph node dissection. In
both patients no bleeding was observed from the liver resection
surface.
Mortality
There were no intra-operative deaths. Four patients died within
30-days as a result of the following: 1 liver failure, 1 multi-organ
failure owing to haemoperitoneum (emergency), 1 septic shock
and 1 stroke. The overall 30-day mortality rate was 3.0% per
procedure (4/133) and 3.7% per patients (4/108). The 30-day
mortality rate for elective surgery was 2.3% (3/128) per procedure
and 2.9% (3/103) per patients.
Another 4 patients (3.7%) died within 90-days after surgery
because of the following: respiratory insufficiency in 2 patients
(metastatic pleural effusions, pneumonia), 1 septic cerebral
embolism as a result of endocarditis and 1 death at home. The
overall 90-day mortality rate was 6.0% per procedure (8/133) and
7.4% per patients (8/108). The 90-day mortality rate for elective
surgery was 4.7% (6/128) per procedure and 5.8% (6/103)
per patients.
Factors related to complications
Because TachoSil® or Surgicel® application seemed to have no
influence on post-operative complications, the data were further
analysed to determine which factors were associated with post-
operative complications, in order to detect potential bias because
of the non-randomized study design.
In univariate analysis, 6 factors were associated with compli-
cations: ASA score 3, duration of surgery >240 min, pre-
operative albumin level < 35 g/dl, right hepatectomy, blood loss
and transfusion (Table 5). Multivariate logistic regression analy-
sis found two independent risk factors for overall complications:
ASA score 3 [P = 0.001; odds ratio (OR): 3.77; 95% confidence
interval (CI): 1.64–8.63] and duration of surgery >240 min
(P = 0.003; OR: 3.10; 95% CI: 1.44–6.67). The risk factors for
complications were equally distributed between both groups
(Tables 1–3).
Subgroup analysis
The data were further analysed to determine whether TachoSil®
was more effective in reducing complications in patients with
extrahepatic procedures, repeat hepatectomy or major hepatec-
tomy. Subgrouping was performed according to the definitions
given in the patients and methods section. Demographic, clinical
and intra-operative data for the subgroups are shown in Table 6.
A difference between the subgroups was a higher number of
patients with colorectal liver metastases in repeat hepatectomy
and extrahepatic procedures vs. major hepatectomy.
Results of the subgroup analysis for TachoSil® vs. Surgicel®
application are shown in Table 7. The overall complication rate
and the liver surgery-specific composite endpoint were signifi-
cantly reduced for the TachoSil® group in major liver resection.
Discussion
The aim of this study was to compare the incidence of post-
operative complications between those patients that received
TachoSil® to the transection surface of the liver vs. those that
received Surgicel®. The present study suggests that routine use of
a carrier-bound fibrin sealant after liver resection does not reduce
Table 1 General characteristics of patients in the ‘TachoSil®’ group
(n = 64) and in the ‘Surgicel®’ group (n = 69)
TachoSil® Surgicel® P
n = 64 (%) n = 69 (%)
Female gender 17 (26.6%) 24 (34.8%) 0.350
Median age (years) 68 64 0.173*
Range 23–86 27–84
Study period
First half (n = 66) 43 (67.2%) 23 (33.3%) <0.001
Second half (n = 67) 21 (32.8%) 46 (66.7%)
Charlson's comorbidity index
Median 6 6 0.865*
Range 0–10 0–12
ASA Score  3 25 (39.1%) 27 (39.1%) 1
Body mass index
Median 25.5 26.2 0.718*
Range 15–40 14–39
Albumin level < 35 g/dl 8 (12.5%) 13 (18.8%) 0.350
Liver disease
Cirrhosis 6 (9.4%) 7 (10.1%) 1
Fibrosis 4 (6.2%) 3 (4.3%) 0.710
Steatosis 30 (46.9%) 25 (36.2%) 0.223
Viral hepatitis 3 (4.7%) 8 (11.6%) 0.210
Diagnosis
Colorectal metastases 39 (60.9%) 38 (55.1%) 0.598
Hepatocellular carcinoma 12 (18.7%) 14 (20.3%) 0.831
Cholangiocarcinoma 6 (9.4%) 5 (7.2%) 0.757
Other diagnosis 7 (10.9%) 12 (17.4%) 0.329
Pre-operative chemotherapy 19 (29.7%) 26 (37.7%) 0.363
Emergency surgery 1 (1.6%) 4 (5.8%) 0.367
Continuous variables* were compared using a Mann–Whitney test.
Categorical variables were compared using Fisher's exact test.
Variables with P < 0.050 are in bold.
ASA, American Society of Anesthesiology.
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the overall complication rate compared with oxidized cellulose
application. However, subgroup analysis found that TachoSil®
may be beneficial in major hepatectomy, as the liver surgery-
specific composite endpoint and overall complications were
reduced in the TachoSil® group.
These findings were in agreement with the study of Briceno
et al.13 who showed a reduction of Clavien-Dindo grade 3 com-
plications for major liver resections in the fibrin sealant group. In
the present study, TachoSil® sealing did not reduce the bile leakage
rate. These findings were in agreement with other reports.12,13
Surgical outcome in the present study was comparable to
published data: the overall major complication rate of 21.8%
(29/133) was similar to 19.6 % reported by Aloia et al.2 and
23.3% reported by Figueras et al.11 The 30-day mortality rate for
elective surgery observed in the present study of 2.3% (per pro-
cedure) or 2.9% (per patient) was similar to the mortality rate
of 2.5% to 3.1% reported by other authors.1,2,11 The liver
surgery-specific composite endpoint (Clavien-Dindo  grade 3)
was registered in 15.8% of all resections (21/133) and was within
the range of data published for the Maastricht cohort (19.2%)
and the Strasbourg cohort (10.7%), where extrahepatic proce-
dures were excluded.3
In the present study, ASA score 3 and duration of surgery
>240 min were risk factors for complications in multivariate
analysis. The ASA classification of physical status (ASA score) was
introduced in 1941 and revised in 1963.26 The ASA score indicates
Table 2 Types of liver resection according to the Brisbane terminology22 and extrahepatic procedures in the TachoSil® group (n = 64) and in
the Surgicel® group (n = 69)
TachoSil® Surgicel® P
n = 64 (%) n = 69 (%)
Major hepatectomy 20 (31.2%) 21a (30.4%) 1
Right hepatectomy (+ segment 1) 13 (0) (20.3%) 13 (2) (18.8%) 1
Extended right hepatectomy 0 1 (1.4%) 1
Left hepatectomy (+ segment 1) 7 (0) (10.9%) 3 (1) (4.3%) 0.195
Trisegmentectomy 4,5,8 0 1 (1.4%) 1
Minor hepatectomy
Bisegmentectomy 2,3 5 (7.8%) 9 (13.0%) 0.402
Bisegmentectomy (other) 18 (28.1%) 19 (27.5%) 1
Segmentectomy and limited resection 21 (32.8%) 23 (33.3%) 1
Resection involving segment 1 3 (4.7%) 5 (7.2%) 0.719
Resection involving segment 4 28 (43.7%) 36 (52.2%) 0.386
Repeat-hepatectomy 12 (18.7%) 13 (18.8%) 1
Extrahepatic procedures
Total 17 (26.6%) 28 (40.6%) 0.101
Colorectal resection 12 (18.7%) 17 (24.6%) 0.529
Otherb 5 (7.8%) 11 (15.9%) 0.186
aIn the Surgicel® group one patient had two bisegmentectomies (four resected segments) and two patients had a bisegmentectomy and
uni-segmentectomy each (three resected segments) classifying those resections as a major hepatectomy.
bOther extrahepatic procedures included: partial resection of the small intestine (n = 4), gastrectomy (n = 2), pancreatectomy (n = 2), partial resection
of the right diaphragm (n = 3), right adrenalectomy (n = 2) and biliodigestive anastomosis (n = 3). Only the main extrahepatic procedure was included.
Categorical variables were compared using Fisher's exact test.
Table 3 Intra-operative data of liver resection and extrahepatic pro-
cedures in the TachoSil® group (n = 64) and in the Surgicel® group
(n = 69)
TachoSil® Surgicel® P
n = 64 (%) n = 69 (%)
Duration of surgery (min)
>240 min 39 (60.9%) 30 (43.5%) 0.056
Median 270 240 0.011*
Range 110–630 110–480
Pringle clamping
Yes 54 (84.4 %) 55 (79.7 %) 0.508
Median clamping time (min) 34 28 0.128*
Range 10–82 8–61
Transfusion
Yes 25 (39.1%) 32 (46.4%) 0.483
Intra-operatively 21 (32.8%) 27 (39.1%) 0.474
Post-operatively 11 (17.2%) 13 (18.8%) 0.825
Median number of units 3 3 0.711*
Range 2–10 2–13
Estimated blood loss (ml)
Median 300 300 0.841*
Range 50–2500 30–2500
Continuous variables* were compared using a Mann–Whitney test.
Categorical variables were compared using Fisher's exact test.
Variables with P < 0.050 are in bold.
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a patient’s anaesthetic risk based on comorbidities. A higher ASA
score was a predictive factor for post-operative complications
in abdominal and vascular surgery.27 Aloia et al. in a large multi-
center study of 2313 patients2 and Belgithi et al. in a study of 747
consecutive liver resections28 have shown a correlation of a higher
ASA score with post-operative complications after liver resections.
Recently, Tzeng et al. reported that an ASA score3, an operation
time >222 min and the extent of liver resection were associated
with an increased risk for venous thromboembolism.29 In the
present study, the median duration of surgery was 240 min and
was increased for a major hepatectomy (270 min), repeat hepate-
ctomy (285 min) and extrahepatic procedures (290 min; Table 6).
A longer operation time probably reflects a more complex or
technically more difficult procedure. Median operation time was
25 min longer for the first 66 patients (43 with TachoSil®) vs. the
next 67 patients (46 with Surgicel®). A learning curve effect can
not be excluded here. It is intuitive that a longer operation
time could increase the peri-operative risk. This observation was
confirmed by other authors.1,2,27,29
The main limitation of the present study was the absence of
randomization. In 2007, the initial choose of TachoSil® for liver
resection was motivated by the authors surgical training, technical
habits and literature data.4,11,12 Surgicel® was already used in the
authors institution for thyroid, pancreatic and digestive surgery.
The Surgicel® Original 10 ¥ 20 cm fleece is a ready to use haemo-
static agent and adheres well to the liver resection surface after
application with gentle pressure (Fig. 2). The main advantage
of Surgicel® over TachoSil® was the lower cost. No patient
required TachoSil® sealing for failure of haemostasis with
Surgicel® application.
A controversial detail of the present study was the routine use
of drainage (except in the cirrhotic liver). Indeed a meta-analysis
by Petrowsky et al. based on three studies with a total of 304
patients showed a higher rate of infected intra-abdominal col-
lections after liver resection in the drainage group vs. the group
without drainage (ORs: 2.83; CI: 0.82–9.71). However, the dif-
ference was not significant (P = 0.70).30 Intra-peritoneal drainage
was widely used after liver resection.11,13,30,31 In the authors
institution drainage was used after liver resection and digestive
surgery for the detection of postoperative bleeding, bile leakage
or a digestive fistula. In the present study, infected intra-
abdominal collections were registered in four patients (3.0%).
Bile leakage subsided with retention of the drain in 8 out of
12 patients. This finding was in agreement with the study of
Kyoden et al.31 who studied the value of prophylactic drainage in
1269 consecutive liver resections. However, only a randomized,
sufficiently powered trial could show if routine drainage is really
worthwhile after liver resection.
Table 4 Post-operative outcome data: overall complications, severity of complications according to the Clavien-Dindo classification,21 liver
surgery-specific composite endpoint according to van den Broek et al.,3 duration of drainage, re-operations, percutaneous radiological
drainage and median hospital stay
TachoSil® Surgicel® P
n = 64 (%) n = 69 (%)
Overall complication rate 40 (62.5%) 43 (62.3%) 1
Severity of overall complications
Clavien-Dindo 1 6 (9.4%) 5 (7.2%) 0.757
Clavien-Dindo 2 22 (34.4%) 21 (30.4%) 0.711
Clavien-Dindo 3 4 (6.2%) 5 (7.2%) 1
Clavien-Dindo 4 5 (7.8%) 7 (10.1%) 0.765
Clavien-Dindo 5 = 90-day mortality 3 (4.7%) 5 (7.2%) 0.719
Major complications (Clavien-Dindo 3, 4 and 5) 12 (18.7%) 17 (24.6%) 0.529
Liver surgery-specific composite endpoint3
All grade of severity 12 (18.7%) 18 (26.1%) 0.406
Clavien-Dindo  3 8 (12.5%) 13 (18.8%) 0.350
Bile leakage 7 (10.9%) 5 (7.2%) 0.551
Median duration of postoperative drainage (days) 6 6 0.490*
Range 2–50 2–45
Re-operation 1 (1.6%) 3 (4.3%) 0.620
Percutaneous radiological drainage 4 (6.2%) 5 (7.2%) 1
Median hospital-stay (days) 13 10 0.096*
Range 5–90 3–90
Continuous variables* were compared using a Mann–Whitney test.
Categorical variables were compared using Fisher's exact test.
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In the present study, subgroup analysis found a reduction of
the liver surgery-specific composite endpoint and overall compli-
cations after major hepatectomy for the TachoSil® group. Why
TachoSil® seems to be more efficient in major vs. minor hepatec-
tomy remains questionable. A more efficient sealing of a large
transection surface in major hepatectomy may be an explication.
However, the transection surface was not measured in the present
study. Subgroup analysis should be regarded with caution, as uni-
dentified bias may be present and because of the small numbers.
Therefore, these findings should be confirmed by a larger rand-
omized trial.
Conclusion
The present study showed no reduction in the overall com-
plication rate, bile leakage rate and hospital stay for routine
TachoSil® sealing vs. Surgicel® application after liver resection.
However, TachoSil® application seems to be beneficial after a
Table 5 Univariate analysis of predictive factors for overall post-operative complications
Complicated Uncomplicated P
n = 83 (%) n = 50 (%)
Median age in years (range) 67 (45–86) 65 (23–85) 0.180*
Female gender 23 (27.7%) 18 (36.0%) 0.337
First half of study (n = 66) 43 (51.8%) 23 (46.0%) 0.592
Second half of study (n = 67) 40 (48.2%) 27 (54.0%)
Emergency surgery 4 (4.8%) 1 (2.0%) 0.649
Cancer 77 (92.8%) 44 (88.0%) 0.533
Charlson Comorbidity Index Score >6 32 (38.6%) 14 (28.0%) 0.260
ASA Score  3 41 (49.4%) 11 (22.0%) 0.001
Body Mass Index < 18.5 5 (6.0%) 4 (8.0%) 0.728
Albumin level < 35 g/l 19 (22.9%) 2 (4.0%) 0.005
Creatinine >100 mmol/l 11 (13.2%) 8 (16.0%) 0.798
Hemoglobin level < 11 g/dl 11 (13.2%) 4 (8.0%) 0.410
Viral hepatitis 6 (7.2%) 5 (10.0%) 0.746
Cirrhosis 8 (9.6%) 5 (10.0%) 1
Fibrosis 5 (6.0%) 2 (4.0%) 0.710
Steatosis 37 (44.6%) 18 (36.0%) 0.367
Pre-operative chemotherapy 30 (36.1%) 15 (30.0%) 0.571
Colorectal liver metastases 51 (61.4%) 26 (52.0%) 0.364
Hepatocellular carcinoma 16 (19.3%) 10 (20.0%) 1
Cholangiocarcinoma 5 (6.0%) 6 (12.0%) 0.329
Other diagnosis 11 (13.2%) 8 (16.0%) 0.798
Repeat-hepatectomy 19 (22.9%) 6 (12.0%) 0.168
Major hepatectomy 30 (36.1%) 11 (22.0%) 0.120
Right hepatectomy 22 (26.5%) 5 (10.0%) 0.026
Left hepatectomy 4 (4.8%) 6 (12.0%) 0.175
Resection involving segment 1 6 (7.2%) 2 (4.0%) 0.493
Resection involving segment 4 40 (48.2%) 24 (48.0%) 1
Median clamping time in min (range) 30 (8–61) 30 (10–82) 0.779*
TachoSil®sealing 40 (48.2%) 24 (48.0%) 1
Extrahepatic procedures 31 (37.3%) 14 (28.0%) 0.344
Median blood loss in ml (range) 300 (30–2500) 200 (30–2500) 0.010*
Duration of surgery >240 min 51 (61.4%) 18 (36.0%) 0.006
Peri-operative transfusion 43 (51.8%) 14 (28.0%) 0.010
Continuous variables* were compared using a Mann–Whitney test
Categorical variables were compared using Fisher's exact test.
ASA, American Society of Anesthesiology.
Variables with P < 0.1 were included in multivariate analysis.
Variables with P < 0.050 are in bold.
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major hepatectomy. Further studies are necessary to confirm
these findings.
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